Science and Research

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

BACKGROUND: First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. PATIENTS AND METHODS: Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. RESULTS: In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%,

  • Borghaei, H.
  • Ciuleanu, T. E.
  • Lee, J. S.
  • Pluzanski, A.
  • Caro, R. B.
  • Gutierrez, M.
  • Ohe, Y.
  • Nishio, M.
  • Goldman, J.
  • Ready, N.
  • Spigel, D. R.
  • Ramalingam, S. S.
  • Paz-Ares, L. G.
  • Gainor, J. F.
  • Ahmed, S.
  • Reck, M.
  • Maio, M.
  • O'Byrne, K. J.
  • Memaj, A.
  • Nathan, F.
  • Tran, P.
  • Hellmann, M. D.
  • Brahmer, J. R.

Keywords

  • Humans
  • Nivolumab/therapeutic use
  • *Carcinoma, Non-Small-Cell Lung/pathology
  • Ipilimumab/adverse effects
  • *Lung Neoplasms/pathology
  • Progression-Free Survival
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Nsclc
  • dual immunotherapy
  • ipilimumab
  • nivolumab
Publication details
DOI: 10.1016/j.annonc.2022.11.006
Journal: Ann Oncol
Pages: 173-185 
Number: 2
Work Type: Original
Location: ARCN
Disease Area: LC
Partner / Member: Ghd
Access-Number: 36414192

DZL Engagements

chevron-down